University of Iowa Study Validates TENS Therapy as Effective Long-Term Solution for Fibromyalgia Pain and Fatigue

University of Iowa researchers find TENS therapy effectively reduces movement-based pain and fatigue in fibromyalgia patients for over six months.

By: AXL Media

Published: Mar 28, 2026, 5:11 AM EDT

Source: Information for this report was sourced from University of Iowa Health Care

A Real-World Breakthrough for Chronic Pain Management

The FM-TIPS study marks a milestone as the first large-scale, real-world trial to evaluate transcutaneous electrical nerve stimulation for patients suffering from fibromyalgia. Led by Kathleen Sluka, the research confirms that adding TENS to standard outpatient physical therapy provides a safe and accessible means of managing a condition often resistant to traditional medicine. Unlike previous controlled laboratory experiments, this study spanned 28 clinics across six healthcare systems, proving that the intervention remains effective despite the complex variables of everyday patient life.

Addressing the Barrier of Movement-Evoked Fatigue

For the millions living with fibromyalgia, the dual burden of pain and exhaustion often makes basic physical activity impossible. While exercise is a primary recommendation for the condition, the pain triggered by movement frequently leads to a cycle of inactivity. The Iowa research team found that TENS is one of the few available interventions that specifically targets this movement-evoked fatigue. By delivering mild electrical pulses through adhesive electrodes, the device effectively blocks pain signals, allowing patients to participate more fully in their physical therapy and daily routines.

Comparative Efficacy Against Pharmacological Options

The findings suggest that the pain-reduction capabilities of TENS are comparable to, or in some cases better than, current FDA-approved medications for fibromyalgia. This is particularly significant given that many pharmacological treatments carry side effects or lose efficacy over time as patients develop a tolerance. In contrast, the study showed that TENS maintained its clinical benefit throughout the six-month observation period. Furthermore, the treatment offered a rare solution for the "whole-body fatigue" that characterizes the disorder, an area where pharmaceutical options have historically fallen short.